MTOR and hepatocellular carcinoma: Antroquinonol displayed anticancer potential for human hepatocellular carcinoma cells by adenosine 5′-monophosphate- (AMP-) activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) pathways [23] and could protect the kidney from immunologic damage via blocking tumor necrosis factor-α (TNF-α) and interleukin-1β- (IL-1β-) mediated inflammatory process [24].